Patent ID: 7666414

Claim:
A method of treating prostate cancer in a subject, comprising administering to the subject two or more doses of an antibody or antigen binding fragment thereof which binds to the extracellular domain of prostate specific membrane antigen (PSMA) and which is coupled to lutetium ( 177 Lu), wherein each dose is about 40 to 65% of the maximum tolerated dose (MID) of the antibody molecule coupled to lutetium ( 177 Lu), to thereby treat the prostate cancer, wherein the antibody or antigen binding fragment thereof comprises at least one of: a light chain variable region comprising the amino acid sequence shown as SEQ ID NO:22, the amino acid sequence shown as SEQ ID NO:50, the light chain variable region amino acid sequence of the antibody produced by the NS0 cell line having ATCC Accession Number PTA-3709, or the light chain variable region amino acid sequence of the antibody produced by the NS0 cell line having ATCC Accession Number PTA-4174; and a heavy chain variable region comprising the amino acid sequence shown as SEQ ID NO:21, the amino acid sequence shown as SEQ ID NO:49, the heavy chain variable region amino acid sequence of the antibody produced by the NSOcell line having ATCC Accession Number PTA-3709, or the heavy chain variable region amino acid sequence of the antibody produced by the NS0 cell line having ATCC Accession Number PTA-4174.